Market Overview

UPDATE: Morgan Stanley Initiates AbbVie at Equal-Weight; Heavy Reliance on Humira

Related ABBV
AbbVie Files for HCV Combination Therapy in U.S. - Analyst Blog
AstraZeneca (AZN) Jumps: Stock Adds 8.8% in Session - Tale of the Tape

Morgan Stanley initiated coverage on AbbVie (NYSE: ABBV) with an Equal-weight rating and a $36 price target.

Morgan Stanley noted, "AbbVie (ABBV) biopharma separated from Abbott. We are EW given heavy reliance on Humira and 6% EV/EBITDA premium to global median, offset by attractive yield. Our $36 PT is based on 4.5% yield (assuming div is boosted 2.5% in Dec '13 to $1.64). … AbbVie generates the majority of its $18B in annual revenues from biologicals, including $9B from Humira, a self-injectable drug for arthritis and other autoimmune disorders. It has a highly experienced mgmt team with a strong track record. We project FCF of $5B+ to support $2.5B+ div and external deals to boost pipeline."

AbbVie closed at $35.12 on Wednesday.

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (ABBV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free